An empirical review of the impact of triplicate prescription of benzodiazepines.
In 1989 New York became the first state to add benzodiazepines to the list of controlled substances requiring a triplicate prescription, allowing the state to track prescribing patterns and target providers, pharmacies, and patients for investigation when misuse is suspected. Studies by the state reporting that regulation has significantly reduced inappropriate prescribing and illicit diversion of benzodiazepines without affecting legitimate prescribing practices are being challenged by other studies showing that patients with legitimate needs for benzodiazepines are being denied them, often after abrupt discontinuation. Several reports indicate a significant increase in the prescribing of benzodiazepine substitutes that are less safe and effective, along with increased overdoses of some substitute drugs. Changes in physicians' legitimate prescribing practices may reflect their fears of the damage to career and peace of mind that follows investigations by regulatory agencies.
Department of Psychiatry, Hartford Hospital, Connecticut 06115.
H I
HI
Schwartz
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D011307:Drug Prescriptions; D004363:Drug Utilization / Q000331:legislation & jurisprudence; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006801:Humans; D009518:New York; D011785:Quality Assurance, Health Care / Q000331:legislation & jurisprudence; D019966:Substance-Related Disorders / Q000517:prevention & control*; D014481:United States
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines